Development of Pediatric Dosing for Mepolizumab in Severe Asthma Based on Extrapolation of Data From Adult Patients and a Phase II Open-Label Pediatric Trial.

Gupta A, Pouliquen IJ, Phipatanakul W, Austin D, Whelan G, Price RG, Finney-Hayward T, Derey S, Steinfeld J

Open source

DOI
10.1002/jcph.70155
Published
2026 Feb
Container
Journal of clinical pharmacology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1002/jcph.70155,
  title = {Development of Pediatric Dosing for Mepolizumab in Severe Asthma Based on Extrapolation of Data From Adult Patients and a Phase II Open-Label Pediatric Trial.},
  author = {Gupta A and Pouliquen IJ and Phipatanakul W and Austin D and Whelan G and Price RG and Finney-Hayward T and Derey S and Steinfeld J},
  year = {2026},
  journal = {Journal of clinical pharmacology},
  doi = {10.1002/jcph.70155},
  url = {https://doi.org/10.1002/jcph.70155}
}

RIS

TY  - JOUR
TI  - Development of Pediatric Dosing for Mepolizumab in Severe Asthma Based on Extrapolation of Data From Adult Patients and a Phase II Open-Label Pediatric Trial.
AU  - Gupta A
AU  - Pouliquen IJ
AU  - Phipatanakul W
AU  - Austin D
AU  - Whelan G
AU  - Price RG
AU  - Finney-Hayward T
AU  - Derey S
AU  - Steinfeld J
PY  - 2026
JO  - Journal of clinical pharmacology
DO  - 10.1002/jcph.70155
UR  - https://doi.org/10.1002/jcph.70155
ER  - 

APA

A, G., IJ, P., W, P., D, A., G, W., RG, P., T, F., S, D., & J, S. (2026). Development of Pediatric Dosing for Mepolizumab in Severe Asthma Based on Extrapolation of Data From Adult Patients and a Phase II Open-Label Pediatric Trial.. Journal of clinical pharmacology. https://doi.org/10.1002/jcph.70155

Source records